MECOM and acute myeloid leukemia: This observation may also have a biologic explanation, as MECOM overexpression is associated with aberrant hypermethylation signature mediated through interactions with DNA methyltransferases (DNMT), providing a rationale for the use of HMA (DNMT inhibitors) in AML with inv(3)/t(3;3) [51].